Travel Vaccine Breaking News

Travel vaccine breaking news brought to you by Vax Before Travel.

Jul 23, 2025 • 1:24 pm CDT
Google Maps July 23, 2025

The ARS Auvergne-Rhône-Alpes states that most dengue cases reported in mainland France involve international travelers who were infected with the mosquito-transmitted virus while visiting a tropical region.

If people return to France infected, dengue symptoms occur on average within 4 to 7 days after the infective bite. These are considered imported cases.

However, recent reports suggest that a local outbreak may occur in July 2025.

Approximately 50 kilometers southwest of Lyon, France, Saint-Chamond, in the Auvergne-Rhône-Alpes region, has confirmed a second locally acquired case of Dengue as of July 15, 2025.

'At this stage, it is not possible to establish a link with the first indigenous case identified in Saint-Chamond, as the investigations are still ongoing,' wrote ARS Auvergne-Rhône-Alpes.

An entomological survey conducted on July 18, 2025, confirmed the presence of tiger mosquitoes in areas frequented by the infected person and informed residents of an adulticide treatment. These mosquitoes carry dengue viruses.

Around one hundred homes in the affected area have been informed.

As of July 23, 2025, Sante Publique France reported a total of four locally acquired cases of Dengue for 2025.

In 2024, France reported 82 locally transmitted cases of dengue fever. Outbreaks were identified in the Provence-Alpes-Côte d'Azur, Occitanie, and Auvergne-Rhône-Alpes regions.

The World Health Organization has classified Dengue as a grade 3 emergency, with an estimated 4 billion people at risk in approximately 110 countries, including areas within the United States, such as Florida and Puerto Rico. 

While numerous countries offer Dengue vaccinations, only Puerto Rico continues to provide a first-generation vaccine to children.

Note: This article was updated on July 24, 2025.

Jul 23, 2025 • 12:18 pm CDT
Google Maps 2025

The South Carolina Department of Public Health (DPH) recently confirmed that a cat and a fox have tested positive for rabies in separate incidents that impacted people. 

As of July 17, 2025, rabies is most commonly found in South Carolina (S.C.) wildlife, including raccoons, skunks, foxes, and bats.

However, most rabies cases in the United States are associated with bat bites, not dog bites.

In Greenville County, the cat that tested positive for rabies was found near Holland Ford and Beech Springs roads in Pelzer, S.C.

In 2024, six of the 81 confirmed rabies cases in S.C. were in Greenville County, which has a population exceeding 500,000.

In Marion County, the fox that tested positive for rabies was found near the intersection of Sandhill and Ellis roads in Marion. One person was exposed and has been referred to their healthcare provider. This fox is the third animal to test positive for rabies in that county in 2025.

There have been 45 cases of rabid animals in S.C. in 2025.

Since 2002, S.C. has averaged approximately 144 positive cases a year.

Terri McCollister, DPH, Rabies Program manager, commented in a press release, “Any mammal can carry and transmit the rabies virus to people or pets. Therefore, give wild and stray animals plenty of space.”

According to the DPH, rabies is a treatable and vaccine-preventable disease. Rabies information for local Public Health offices is available at dph.sc.gov/RabiesContacts. For more information on rabies, visit  dph.sc.gov/rabies or cdc.gov/rabies.

Jul 23, 2025 • 4:57 am CDT
US CDC July 22, 2026

The WHO Director-General recently determined that the upsurge of mpox cases in Africa continues to meet the criteria of a public health emergency of international concern and issued temporary recommendations to States Parties as of July 10, 2025.

The first human case of mpox was recorded in 1970 in the Democratic Republic of the Congo, which has subsequently spread to other central and western African countries. 

According to the U.S. Centers for Disease Control and Prevention (CDC), outbreaks of clade II mpox have been reported in Liberia and Sierra Leone, where mpox is endemic.

The CDC's updated Level 2 - Practice Enhanced Precautions, Travel Health Advisory states that, unlike the ongoing global clade II mpox outbreak, which began in May 2022, these outbreaks have affected males and females approximately equally. 

Furthermore, person-to-person transmission has occurred during this outbreak, including through sexual or other intimate contact.

Previously, the Ministry of Health in Cameroon confirmed the first case of mpox (Clade I) in a child from Ayos district, as of July 9, 2025.

The CDC recommends mpox vaccination (JYNNEOS®, MVA-BN®, IMVAMUNE®) for travelers to Liberia and Sierra Leone.

This advice is essential as millions of international travelers are visiting Africa.

According to the World Tourism Barometer from UN Tourism, Africa attracted approximately 74 million tourists in 2024.

Jul 23, 2025 • 4:38 am CDT
Maps 2025

Local media (ANI) reported that the Afghanistan Ministry of Public Health recently launched a polio vaccination campaign targeting 7.3 million children across 19 provinces of Afghanistan.

Healthcare providers have emphasized the crucial role of public awareness and ongoing investment in eradicating polio. Dr. Mojtaba Sufi, a health expert in the Islamic Emirate of Afghanistan, reiterated in a news article, "The only effective way to prevent polio is through vaccination, and the international community provides these vaccines.

This new vaccination campaign is essential as Afghanistan is affected by ongoing endemic wild poliovirus (WPV) transmission. 

The total number of WPV1 cases in 2025 is two, which compares to 2024 when 25 cases were confirmed.

As of July 23, 2025, the U.S. CDC and the WHO's International Travel and Health recommend that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors staying for more than 4 weeks) from areas infected with poliovirus, such as Afghanistan, should receive an additional dose of oral or inactivated polio vaccine within 4 weeks to 12 months after travel.

Additionally, a booster dose may be recommended for specific travelers.

Currently, the CDC lists 41 countries as being at risk for poliovirus.

Jul 23, 2025 • 4:13 am CDT
Florida Dept of Health July 2025

As the respiratory syncytial virus (RSV) season expands in the state of Florida, the most significant US real-world study of a single-dose long-acting antibody designed to help prevent RSV lower respiratory tract disease in infants successfully met both of its co-primary endpoints.

The full results from the "Effectiveness of nirsevimab against RSV and RSV-related events in infants" study have been published in PEDIATRICS®, an official journal of the American Academy of Pediatrics, on July 22, 2025.

Ayman Chit, Head of North America Medical, Vaccines, Sanofi, commented in a press release, "These results support BEYFORTUS (nirsevimab) as a groundbreaking advancement in infant RSV disease prevention."

"With more than 40 real-world evidence studies to date, this latest study further strengthens the well-established body of data that shows that BEYFORTUS protects against RSV disease to help safeguard the health of all babies, regardless of whether they are born before or during the RSV season."

According to the Florida Department of Health, RSV is a common respiratory virus that typically causes mild, cold-like symptoms. Young children and older adults, especially those with certain underlying health conditions, are at higher risk for severe illness from RSV.

Florida’s RSV season is longer than that of the rest of the nation and exhibits distinct regional patterns. For this reason, the state is broken up into five RSV regions, each with its own RSV season.

Jul 22, 2025 • 3:57 pm CDT
by Veronika Andrews Andrews

Austin Public Health (APH) announced yesterday that its wastewater surveillance in Travis County has detected the presence of the measles virus collected during the first week of July 2025.

As of July 21, 2025, this detection may indicate an undetected case or cases of measles in the local community that exceeds 1 million residents.

Furthermore, Austin adds another 50,000 college students each year during August and hosts over 100,000 football fans most weekends in the Fall.

So far in 2025, only two measles cases have been confirmed among Travis County residents, both of which were linked to exposure during international travel.

However, the State of Texas has reported numerous measles cases in western counties, as well as in Dallas and Houston counties.

Measles is highly contagious and is spread through the air when an infected person coughs or sneezes. The disease can actively linger in the air and on surfaces for up to two hours. If someone breathes contaminated air or touches infected surfaces and then their eyes, nose, or mouth, they can become infected.

APH says if one person has measles, 9 out of 10 unvaccinated people nearby will become infected if they are not protected.

APH offers the MMR vaccine for uninsured and underinsured Austinites at its Shots for Tots and Big Shots clinics.

Jul 22, 2025 • 8:29 am CDT
Health Canada 2025

With an unexpected number of chikungunya outbreaks reported in the Region of the Americas in 2025, Canada is taking action to ensure an ample supply of vaccines available.

In the past 20 years, the mosquito-transmitted chikungunya virus has emerged across many popular travel destinations.

Bavarian Nordic A/S announced today that Health Canada has accepted for review the Company's application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.

The Directorate's acceptance of the application screening confirms that the New Drug Submission is complete, initiating a standard review procedure that may support approval of the vaccine in the first half of 2026.

Paul Chaplin, President and CEO of Bavarian Nordic, stated in a press release on July 22, 2025, "Pending approval, this vaccine will further strengthen our offering for Canadians seeking protection against serious diseases when traveling the world."

The VLP vaccine was approved by the U.S. Food and Drug Administration, the European Commission, and the United Kingdom in May 2025 under the trade name VIMKUNYA®.

In the U.S., VIMKUNYA is commercially available at clinics and pharmacies.

Jul 22, 2025 • 7:08 am CDT
Google Maps July 22, 2025

The Mississippi State Department of Health (MSDH) recently issued a health alert confirming an increase in pertussis (whooping cough) cases in the state.

As of July 10, 2025, 80 cases have been reported so far this year. This total is an increase from 2024, when the MSDH reported 49 cases.

As of July 22, 2025, no related fatalities have been reported.

Most (76%) of this year's cases have occurred in children less than 18 years of age. Of the 73 age-eligible cases for pertussis vaccination, 28 were not vaccinated.

While cases have been reported statewide, 40% were identified in northeast Mississippi.

According to the U.S. CDC, reported cases of pertussis have increased across the United States. Preliminary data show that more than six times as many cases were reported in 2024 compared to 2023. 

The CDC states that there's no distinct seasonal pattern to pertussis; however, past trends suggest that cases may increase in the summer and fall.

Pertussis is transmitted from person to person through respiratory droplets or contact with airborne droplets. Patients are considered infectious from the onset of symptoms until three weeks after the start of high-pitched coughing fits, or until they have completed five days of antibiotics.

Vaccination, one of the safest and most effective ways to protect against pertussis, is recommended for everyone. Two types of combination vaccines include protection against pertussis, as well as diphtheria and tetanus: DTaP and Tdap.

DTaP is recommended for younger children, while Tdap is recommended for older children, pregnant women, and adults.

Recommended treatment includes antibiotics within three weeks of cough onset in people 1 year of age and older, and within six weeks of cough onset in infants younger than 1 year old and pregnant women.

MSDH offers vaccinations to children and uninsured adults at county health departments. To make an appointment, visit msdh.ms.gov/pertussis or call (855) 767-0170.

Jul 21, 2025 • 12:54 pm CDT
FDH July 2025

As summer vacation season 2025 reaches a peak, the state of Florida recently reported that numerous individuals have been diagnosed with travel-related diseases in several counties.

As of July 12, 2025, Florida Department of Health confirmed Escambia and Miami-Dade counties remain under mosquito-borne illness alerts.

And St. Johns and Brevard counties have issued Mosquito-Borne Illness Advisories in 2025.

The diagnosed diseases in Florida include four travel-related cases of chikungunya. The countries of origin were Bolivia, Brazil, Indonesia, and Sri Lanka.

A total of 105 cases of dengue fever were reported among individuals who had traveled internationally, with 49 cases of DENV-4 originating from Cuba. Additionally, three locally acquired dengue cases (DEN-3, DENV-4) were reported in Miami-Dade (2) and Brevard (1) counties in 2025.

And 21 travel-related malaria cases have been confirmed in Florida, primarily in people visiting from Africa.

While not travel-related, four people in Florida have died from infections caused by the bacterium Vibrio vulnificus, commonly known as the "flesh-eating" bacterium, in 2025. Last year, 11 cases were confirmed.

From an alert perspective, no country has issued a Travel Health Advisory focused on the state of Florida as of July 21, 2025. However, routine and travel-related vaccines are recommended for many people.

 

Jul 21, 2025 • 10:07 am CDT
US CDC July 2025

In 2025, the United States reached an unfortunate milestone with a record number of measles cases, leading many patients to look for medication.

According to a press release issued today by NanoViricides, Inc., the company has made significant progress in developing a drug to combat measles.

On July 21, 2025, NanoViricides stated NV-387 showed strong antiviral effectiveness against the measles virus.

"NV-387 is on its way to become the very first drug to treat Measles," commented Anil R. Diwan, PhD, adding, "Measles cases are skyrocketing globally, and the world needs a drug."

NV-387 is a clinical-stage, broad-spectrum antiviral drug designed to act as a decoy for a cell, presenting to the virus the very features it requires for binding to the cell. Upon binding, the virus particle is destroyed, preventing infection.

While most measles cases can be prevented through vaccination, the percentage of the population that would not benefit from vaccination continues to increase due to chronic diseases and immunological deficiencies.

Thus, a treatment for measles is of paramount importance to the global health community.

Jul 21, 2025 • 9:47 am CDT
US Dept of State July 2025

Amidst the prime summer vacation season, the United States and United Kingdom have issued 'Do Not Travel' advisories for the Republic of Trinidad and Tobago.

As of July 18, 2025, both countries reported that the Government of Trinidad and Tobago has declared a nationwide State of Emergency. Anyone visiting this Caribbean vacation destination this summer should expect an increased police and military presence.

As a reminder, the U.S. Embassy advises government personnel to avoid traveling to areas such as Laventille (including Picadilly Street and Charlotte Street between Oxford Street and Park Street), Beetham, Sea Lots, Cocorite, and the interior of Queen's Park Savannah, and to refrain from visiting these places after dark.

If you plan to visit Trinidad and Tobago in 2025, the U.S. CDC recommends various routine and travel vaccinations, including those for measles, typhoid, and yellow fever. Travel vaccines are commercially offered at clinics and pharmacies in the U.S.

Jul 21, 2025 • 9:26 am CDT
US CDC July 2025

The United States is currently in the midst of the annual tick season; however, new data indicate fewer tick bites than in most seasons.

This data is very positive as it indicates the number of Lyme Disease cases in the U.S. will be reduced.

As of July 21, 2025, the U.S. Centers for Disease Control and Prevention (CDC) reported a decreasing tick-bite trend when compared to the previous year.

While there are nearly 900 species of ticks globally, only a handful pose a significant risk to humans, such as those that cause Lyme Disease.

However, since 1995, the range of Lyme disease cases has expanded significantly, migrating from Lyme, Connecticut, decades ago, now reaching into the upper Midwest, such as Michigan, which reported 1,215 cases in 2024.

From a disease prevention perspective, without an approved vaccine, the best tactic is to take precautions to avoid being bitten by ticks when outdoors in 2025.

Jul 19, 2025 • 7:42 am CDT
Colombia Health Ministry 2025

The Department of Tolima in the Republic of Colombia recently reported 100 confirmed cases of yellow fever, with a total of 35 related fatalities.

Tolima reported its first case of yellow fever in October 2024, marking the first case in the country since 2000. Within the month, yellow fever cases were reported across the rural municipalities of Cunday, Prado, Purificación, and Villarrica in Tolima.

While yellow fever is endemic throughout most of Colombia, cases are seldom reported in high-altitude areas in the Andean region. The Tolima department is located in the centre-west of the Andean region, at an average elevation of 700 meters above sea level.

This makes the emergence of the disease in the region remarkable, wrote the health department in February 2025.

"The main prevention strategy against yellow fever is vaccination. In the department of Tolima, people between 1 and 59 years of age should be vaccinated. It's important to have adequate and effective protection against the disease," explained Juan Pablo Escobar, Infectious Disease Specialist and Pediatrician, last year.

As of July 19, 2025, yellow fever vaccines are offered in Colombia and recommended for international travelers visiting endemic areas. In 2024, 6.7 million travelers visited Colombia, setting a new record for tourism in this South American country.

The YF-VAX vaccine is commercially available in the United States at certified travel clinics and pharmacies.

Jul 18, 2025 • 11:39 am CDT
Google Maps July 18, 2025

The Republic of Mauritius today announced its adoption of an innovative strategy to combat mosquito-borne diseases through the implementation of the Sterile Insect Technique.

This method involves releasing sterilised male mosquitoes into the wild to mate with females, thereby reducing the mosquito population and containing the spread of diseases such as Chikungunya and Dengue.

This program is essential as the island of Mauritius has already reported over 1,500 Chikungunya cases in 2025.

Furthermore, France's neighboring departments reported a surge in Chikungunya cases in the Indian Ocean, east of Africa.

In a statement published on July 18, 2025, the Minister highlighted that the Sterile Insect Technique has proven effective during a pilot phase and is safer than traditional methods such as larviciding and fogging, which rely on chemical insecticides.

He noted that while current cases of mosquito-borne diseases remain low—around 40 cases of Chikungunya and none of Dengue—now is the time to prepare for the high-risk summer season.

The Sterile Insect Technique has been implemented over the past two to three years and has resulted in a 70% reduction in the mosquito population across a 20-hectare area in Port Louis.

While there is no specific treatment for Chikungunya infections, two vaccines are currently available in various countries, including the United States.

Jul 18, 2025 • 7:39 am CDT
Pixabay 2025

With about one million people developing herpes zoster (shingles) in the US each year, simplifying the vaccination process is essential for at-risk seniors.

Approximately 99% of older adults have the virus that causes shingles inside their bodies.

With 55 million Americans aged 65 or older, many of whom live in California, Florida, and Texas, accessing the US Food and Drug Administration (FDA)-approved Shingrix® vaccine is a priority.

GSK plc, the manufacturer of Shingrix, announced that the FDA has recently approved a prefilled syringe presentation, which eliminates the need to reconstitute the vaccine separately before administration, thereby simplifying the vaccine administration process for healthcare professionals.

Brigid Groves, Vice President of Professional Affairs at the American Pharmacists Association, stated in a press release on July 17, 2025, "The prefilled syringe presentation of GSK's shingles vaccine is good news, providing a convenient method of administration."

"The FDA approval is a positive step toward driving prevention of this painful disease, and as a practicing pharmacist, I welcome the availability of this new presentation."

The Centers for Disease Control and Prevention (CDC) recommends two doses of GSK's shingles vaccine to prevent shingles and related complications in adults aged 50 years or older. Additionally, two doses are recommended for adults aged 19 years or older who are or will be immunocompromised or immunosuppressed.

 The CDC states that as people age, the strength of their immune system's response to infection wanes, increasing the risk of developing shingles.

Additionally, Shingrix vaccination may play a role in delaying the onset of dementia.

Over the past few years, various studies have reported causal evidence that herpes zoster vaccination may prevent a proportion of dementia cases.